कंपनी का अवलोकन
Kyntra Bio, Inc. operates as a biopharmaceutical entity dedicated to discovering, developing, and commercializing therapeutics designed to address serious unmet medical needs. The company functions within the broader Healthcare sector and specifically within the Biotechnology industry, focusing on the creation of innovative treatments such as FG-3246, an antibody-drug conjugate targeting CD46 for metastatic castration-resistant prostate cancer. As of the latest data, the company maintains a market capitalization of $29.10M and employs a workforce of 34 individuals to support its research and development initiatives. The annual revenue generated over the trailing twelve months stands at $6.44M, indicating that the firm operates with a relatively modest revenue scale typical for early-stage biotechnology companies where capital is heavily allocated toward clinical trials rather than mass production or sales. This specific market capitalization combined with the limited revenue stream suggests that Kyntra Bio is currently in a growth phase where the majority of its value proposition is derived from the potential future success of its pipeline assets rather than established commercial cash flows.
वित्तीय स्वास्थ्य
Over the trailing twelve-month period, the company reported a revenue of $6.44M, a net income of $-58,204,000, and an EBITDA of $-44,594,000. The substantial disparity between the $6.44M revenue and the negative net income of $-58,204,000 reveals a cost structure where operating expenses, likely driven by research, development, and clinical trial costs, significantly exceed total sales revenue. Despite the negative net income, the company reports a positive Free Cash Flow of $5.11M, which indicates that the business retains enough cash from operations after capital expenditures to provide a degree of financial flexibility for ongoing R&D activities without needing immediate external financing. The gross margin stands at -273.8%, the operating margin is -1058.7%, and the profit margin is reported as 2848.6%, a figure that reflects the unusual accounting dynamics in pre-commercial biotechnology where non-operating income or specific allocation methods can result in profit margins that diverge from traditional operational performance metrics. On the balance sheet, the company holds $88.98M in cash against $19.56M in debt, resulting in a debt-to-equity ratio of 437.10, which technically indicates a leveraged position due to the negative equity implied by the losses, yet the high cash reserves suggest a conservative stance against liquidity risk. The current ratio is 3.39, signaling strong short-term liquidity and the ability to cover short-term obligations with its current assets. Return on Equity is N/A due to negative equity, while Return on Assets stands at -17.0%, revealing that the assets are currently generating negative returns, a common characteristic for biotech firms investing heavily in long-term projects before product approval.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is N/A because the company is currently unprofitable, while the forward P/E is listed as -0.70, implying that analysts or market models project continued negative earnings in the near term. The price-to-book ratio is -0.97, which indicates that the market valuation is effectively zero or negative relative to the book value, a standard metric for loss-making companies where the market price does not reflect the historical asset book value due to the intangible nature of the pipeline. The price-to-sales ratio is 4.52, and the EV/EBITDA is 0.13; these alternative valuation metrics suggest that investors are pricing the stock based on revenue multiples rather than earnings power, reflecting high risk and high potential reward associated with the drug development pipeline. The stock has traded between a 52-week high of $12.60 and a 52-week low of $4.85, and given the market cap of $29.10M and recent price action, the share price currently sits within this established volatility range, reflecting the uncertainty surrounding clinical outcomes. The beta value is 0.90, which means the stock's price volatility is roughly in line with the broader market, suggesting it does not exhibit extreme sensitivity to general market swings despite its specific biotechnology sector risks.
Growth & Income
The company experienced a revenue growth rate of -59.3% year-over-year, while earnings growth is N/A due to the absence of positive earnings in the prior period. The decline in revenue year-over-year indicates a contraction in sales, which is typical for biotechnology firms transitioning between clinical phases or managing supply chain limitations, rather than indicating a fundamental business failure at this early stage. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available earnings and cash flow are reinvested directly into research and development activities rather than being distributed to shareholders. This reinvestment strategy is essential for a biopharmaceutical company aiming to advance its FG-3246 asset through clinical trials toward potential commercialization. Overall, the growth and income profile of Kyntra Bio is characterized by significant revenue contraction and a complete absence of dividend income, highlighting a capital-intensive growth model that relies entirely on future asset approvals to generate value.